A sensitive and specific ELISA detects methionine sulfoxide-containing apolipoprotein A-I in HDL

Journal of Lipid Research

Volumn 50, Issue 3, 2009, Pages 586-594

  Wang, Xiao Suo ^a   Shao, Baohai ^b   Oda, Michael N ^c   Heinecke, Jay W ^b   Mahler, Stephen ^d   Stocker, Roland ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Dysfunctional HDL; Lipid hydroperoxides; Myeloperoxidase; Oxidative stress; Protein oxidation; Reactive nitrogen species

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; HYDROGEN PEROXIDE; HYPOCHLOROUS ACID; LOW DENSITY LIPOPROTEIN; METHIONINE SULFOXIDE; MONOCLONAL ANTIBODY; PEROXYNITRITE; DRUG DERIVATIVE; METHIONINE; RECOMBINANT PROTEIN;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; ANIMAL; BLOOD; BLOOD ANALYSIS; CHEMISTRY; GENETICS; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; OXIDATION REDUCTION REACTION; SITE DIRECTED MUTAGENESIS; STATISTICS;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; APOLIPOPROTEIN A-I; BLOOD CHEMICAL ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPOPROTEINS, HDL; MALE; METHIONINE; MICE; MIDDLE AGED; MUTAGENESIS, SITE-DIRECTED; OXIDATION-REDUCTION; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 64349091283     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.D800042-JLR200     Document Type: Article

References (32)

1. Stocker, R., and J. F. Keaney, Jr. 2004. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84: 1381-1478.
2. Niu, X., V. Zammit, J. M. Upston, R. T. Dean, and R. Stocker. 1999. Co-existence of oxidized lipids and a-tocopherol in all lipoprotein fractions isolated from advanced human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 19: 1708-1718.
3. Barter, P. J., S. Nicholls, K. A. Rye, G. M. Anantharamaiah, M. Navab, and A. M. Fogelman. 2004. Antiinflammatory properties of HDL. Circ. Res. 95: 764-772.
4. Daugherty, A., J. L. Dunn, D. L. Rateri, and J. W. Heinecke. 1994. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94: 437-444.
5. Hazell, L. J., L. Arnold, D. Flowers, G. Waeg, E. Malle, and R. Stocker. 1996. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J. Clin. Invest. 97: 1535-1544.
6. Anantharamaiah, G. M., T. A. Hughes, M. Iqbal, A. Gawish, P. J. Neame, M. F. Medley, and J. P. Segrest. 1988. Effect of oxidation on the properties of apolipoproteins A-I and A-II. J. Lipid Res. 29: 309-318.
7. Garner, B., P. K. Witting, A. R. Waldeck, J. K. Christison, M. Raftery, and R. Stocker. 1998. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that correlates with lipid peroxidation and can be enhanced by a-tocopherol. J. Biol. Chem. 273: 6080-6087.
8. Garner, B., A. R. Waldeck, P. K. Witting, K-A. Rye, and R. Stocker. 1998. Oxidation of high density lipoproteins. II. Evidence for direct reduction of HDL lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J. Biol. Chem. 273: 6088-6095.
9. Oram, J. F., and J. W. Heinecke. 2005. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol. Rev. 85: 1343-1372.
10. Bergt, C., S. Pennathur, X. Fu, J. Byun, K. O'Brien, T. O. McDonald, P. Singh, G. M. Anantharamaiah, A. Chait, J. Brunzell, et al. 2004. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. USA. 101: 13032-13037.
11. Zheng, L., B. Nukuna, M. L. Brennan, M. Sun, M. Goormastic, M. Settle, D. Schmitt, X. Fu, L. Thomson, P. L. Fox, et al. 2004. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114: 529-541.
12. Peng, D. Q., Z. Wu, G. Brubaker, L. Zheng, M. Settle, E. Gross, M. Kinter, S. L. Hazen, and J. D. Smith. 2005. Tyrosine modification is not required for myeloperoxidase-induced loss of apolipoprotein A-I functional activities. J. Biol. Chem. 280: 33775-33784.
13. Shao, B., M. N. Oda, C. Bergt, X. Fu, P. S. Green, N. Brot, J. F. Oram, and J. W. Heinecke. 2006. Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J. Biol. Chem. 14: 9001-9004.
14. Shao, B., G. Cavigiolio, N. Brot, M. N. Oda, and J. W. Heinecke. 2008. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc. Natl. Acad. Sci. USA. 105: 12224-12229.
15. Pennathur, S., C. Bergt, B. Shao, J. Byun, S. Y. Kassim, P. Singh, P. S. Green, T. O. McDonald, J. Brunzell, A. Chait, et al. 2004. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J. Biol. Chem. 279: 42977-42983.
16. Pankhurst, G., X. L. Wang, D. E. Wilcken, G. Baernthaler, U. Panzenbóck, M. Raftery, and R. Stocker. 2003. Characterization of specifically oxidized apolipoproteins in mildly oxidized high density lipoprotein. J. Lipid Res. 44: 349-355.
17. Brock, J. W., A. J. Jenkins, T. J. Lyons, R. L. Klein, E. Yim, M. Lopes-Virella, R. E. Carter, S. R. Thorpe, and J. W. Baynes. 2008. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J. Lipid Res. 49: 847-855.
18. Baynes, J. W., and S. R. Thorpe. 1999. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 48: 1-9.
19. Sattler, W., D. Mohr, and R. Stocker. 1994. Rapid isolation of lipoproteins and assessment of their peroxidation by HPLC postcolumn chemiluminescence. Methods Enzymol. 233: 469-489.
20. Woodward, M., K. D. Croft, T. A. Mori, H. Headlam, X. S. Wang, C. Suarna, M. J. Raftery, S. W. Macmahon, and R. Stocker. 2009. The association between both lipid and protein oxidation and the risk of fatal or non-fatal coronary heart disease in a human population. Clin. Sci. 116: 53-60.
21. Ryan, R. O., T. M. Forte, and M. N. Oda. 2003. Optimized bacterial expression of human apolipoprotein A-I. Protein Expr. Purif. 27: 98-103.
22. Shao, B., and J. W. Heinecke. 2008. Using tandem mass spectrometry to quantify site-specific chlorination and nitration of proteins: model system studies with high-density lipoprotein oxidized by myeloperoxidase. Methods Enzymol. 440: 33-63.
23. Bowry, V. W., K. K. Stanley, and R. Stocker. 1992. High density lipoprotein is the major carrier of lipid hydroperoxides in fasted human plasma. Proc. Natl. Acad. Sci. USA. 89: 10316-10320.
24. Sattler, W., J. K. Christison, and R. Stocker. 1995. Cholesterylester hydroperoxide reducing activity associated with isolated high- and low-density lipoproteins. Free Radic. Biol. Med. 18: 421-429.
25. Mashima, R., Y. Yamamoto, and S. Yoshimura. 1998. Reduction of phosphatidylcholine hydroperoxide by apolipoprotein A-I: purification of the hydroperoxide-reducing proteins from human blood plasma. J. Lipid Res. 39: 1133-1140.
26. Nakano, T., and A. Nagata. 2005. Oxidative susceptibility of apolipoprotein AI in serum. Clin. Chim. Acta. 362: 119-124.
27. Nakano, T., and A. Nagata. 2003. Immunochemical detection of circulating oxidized high-density lipoprotein with antioxidized apolipoprotein A-I monoclonal antibody. J. Lab. Clin. Med. 141: 378-384.
28. Nakajima, T., Y. Sakagishi, T. Katahira, A. Nagata, T. Kuwae, H. Nakamura, I. Inoue, K. Takahashi, S. Katayama, and T. Komoda. 1995. Characterization of a specific monoclonal antibody 9F5-3a and the development of assay system for oxidized HDL. Biochem. Biophys. Res. Commun. 217: 407-411.
29. Nakajima, T., T. Matsunaga, S. Kawai, S. Hokari, I. Inoue, S. Katayama, A. Nagata, and T. Komoda. 2004. Characterization of the epitopes specific for the monoclonal antibody 9F5-3a and quantification of oxidized HDL in human plasma. Ann. Clin. Biochem. 41: 309-315.
30. Panzenbock, U., and R. Stocker. 2005. Formation of methionine sulfoxide-containing specific forms of oxidized high-density lipoproteins. Biochim. Biophys. Acta. 1703: 171-181.
31. Barter, P., A. M. Gotto, J. C. LaRosa, J. Maroni, M. Szarek, S. M. Grundy, J. J. Kastelein, V. Bittner, and J. C. Fruchart. 2007. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357: 1301-1310.
32. Panzenböck, U., L. Kritharides, M. Raftery, K. A. Rye, and R. Stocker. 2000. Oxidation of methionine residues to methionine sulfoxides does not decrease potential anti-atherogenic properties of apolipoprotein A-I. J. Biol. Chem. 275: 19536-19544.